Form 8-K IDEAYA Biosciences, Inc. For: Sep 23
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
Go back to Form 8-K IDEAYA Biosciences, Inc. For: Sep 23
September 24, 2024 6:14 AM EDT
RBC Capital analyst Gregory Renza reiterated an Outperform rating and $61.00 price target on Ideaya Biosciences (NASDAQ: IDYA).
The analyst comments "Our key takeaway from IDYA's call this morning is a more refined blueprint for daro's regulatory path with positive ph.II data and the... More
September 23, 2024 4:34 PM EDT
Citi analyst Yigal Nochomovitz reiterated a Buy rating and $58.00 price target on Ideaya Biosciences (NASDAQ: IDYA).
The analyst comments "The Ph2 neoadjuvant UM data (including the prior IST) were in-line with our expectations for very substantial efficacy reflecting a 61% eye preservation rate among... More
September 23, 2024 3:48 PM EDT
Goldman Sachs analyst Corinne Jenkins raised the price target on Ideaya Biosciences (NASDAQ: IDYA) to $48.00 (from $47.00) while maintaining a Buy rating.
The analyst comments "DYA announced interim results from an ongoing Ph2 company-sponsored and investigator-sponsored study of darovasertib (daro) in neoadjuvant uveal melanoma (UM). Per the update, 49% (N=49) of patients achieved tumor shrinkage of 30%, while 61% (N=31) in the enucleation-evaluable cohort achieved eye preservation.... More
September 23, 2024 3:45 PM EDT
Stifel analyst Ben Burnett lowered the price target on Ideaya Biosciences (NASDAQ: IDYA) to $66.00 (from $68.00) while maintaining a Buy rating.
The analyst comments "We think the clinical data for darovasertib in the neoadjuvant setting are good, but that the stock... More
September 23, 2024 1:42 PM EDT
BTIG analyst Justin Zelin reiterated a Buy rating and $62.00 price target on Ideaya Biosciences (NASDAQ: IDYA).
The analyst comments ": IDYA reported updated data from the co-sponsored trial of darovasertib in neoadjuvant uveal melanoma (UM) and provided details on Ph 3 strategy in this setting. Big picture,... More
